Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ascletis Pharma, Inc. ( (HK:1672) ) has issued an announcement.
Ascletis Pharma Inc. has announced the selection of ASC36, a once-monthly subcutaneously administered amylin receptor agonist, for clinical development targeting obesity. The preclinical studies indicate that ASC36 offers a significantly longer half-life and greater weight reduction compared to existing treatments, positioning it as a potentially best-in-class therapy. The company plans to submit an Investigational New Drug Application to the FDA by the second quarter of 2026, which could enhance its market positioning in the obesity treatment sector.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$12.84 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biotechnology company focused on developing innovative treatments for metabolic diseases, including obesity. The company utilizes advanced technologies such as Artificial Intelligence-Assisted Structure-Based Drug Discovery and Ultra-Long-Acting Platform to create novel therapeutic solutions.
Average Trading Volume: 9,112,144
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.16B
See more data about 1672 stock on TipRanks’ Stock Analysis page.